Clinical trials / NCT05951179
NCT05951179Phase 2Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Study sponsor: Protara Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2031-10Estimated
Enrollment · participants131Estimated
Source updated2026-08-24Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 Measure: Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002

+ After

Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002

Primary completion date changed

− Before

May 2030

+ After

Oct 2031

Check registry source

· 1 field changed

Planned enrollment increased by 4 participants

− Before

127 participants (planned)

+ After

131 participants (planned)

Check registry source